0001564590-20-051334 | 10-Q | XBRL Viewer

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Nov. 01, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES, INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, $0.000001 par value per share
Security Exchange Name	NASDAQ
Entity File Number	001-16537
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Entity Common Stock, Shares Outstanding		71,732,752
Document Quarterly Report	true
Document Transition Report	false

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 162,859	$ 75,715
Short-term investments	72,961	80,623
Accounts receivable, net of allowance for doubtful accounts of $3,751 and $2,666	30,638	36,948
Inventories	30,488	23,155
Prepaid expenses	2,527	2,433
Other current assets	3,504	5,676
Total current assets	302,977	224,550
Noncurrent Assets:
Property, plant and equipment, net	39,056	30,339
Operating right-of-use assets, net	4,682	4,996
Finance right-of-use assets, net	1,462	1,951
Intangible assets, net	18,111	14,674
Goodwill	39,480	36,201
Long-term investments	27,841	33,420
Other noncurrent assets	2,801	3,164
Total noncurrent assets	133,433	124,745
TOTAL ASSETS	436,410	349,295
Current Liabilities:
Accounts payable	14,377	9,567
Deferred revenue	5,311	3,713
Accrued expenses and other current liabilities	15,147	14,288
Finance lease liability	536	613
Operating lease liability	1,092	1,032
Acquisition-related contingent consideration obligation	764	3,500
Total current liabilities	37,227	32,713
Noncurrent Liabilities:
Finance lease liability	1,025	1,372
Operating lease liability	3,848	4,206
Acquisition-related contingent consideration obligation	3,176	112
Other noncurrent liabilities	2,493	2,848
Deferred income taxes	749	899
Total noncurrent liabilities	11,291	9,437
TOTAL LIABILITIES	48,518	42,150
Commitments and contingencies (Note 11)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 71,611 and 61,731 shares issued and outstanding	0	0
Additional paid-in capital	502,802	401,814
Accumulated other comprehensive loss	(15,595)	(12,136)
Accumulated deficit	(99,315)	(82,533)
Total stockholders' equity	387,892	307,145
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 436,410	$ 349,295

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 3,751	$ 2,666
Preferred stock, par value	$ 1	$ 1
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 1	$ 1
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	71,611,000	61,731,000
Common stock, shares outstanding	71,611,000	61,731,000

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
NET REVENUES:
Total revenue	$ 48,011	$ 35,989	$ 108,866	$ 104,937
COST OF PRODUCTS AND SERVICES SOLD	17,722	14,343	45,182	40,193
Gross profit	30,289	21,646	63,684	64,744
OPERATING EXPENSES:
Research and development	8,007	4,619	20,575	13,525
Sales and marketing	7,849	8,955	25,339	23,937
General and administrative	10,108	7,556	30,442	23,748
Change in the estimated fair value of acquisition-related contingent consideration	(60)	(2,387)	390	(843)
Gain on sale of business		(10,149)		(10,149)
Total operating expenses	25,904	8,594	76,746	50,218
Operating income (loss)	4,385	13,052	(13,062)	14,526
OTHER INCOME	314	1,195	1,960	2,243
Income (loss) before income taxes	4,699	14,247	(11,102)	16,769
INCOME TAX EXPENSE	3,659	1,169	5,680	2,551
NET INCOME (LOSS)	$ 1,040	$ 13,078	$ (16,782)	$ 14,218
INCOME (LOSS) PER SHARE:
BASIC	$ 0.01	$ 0.21	$ (0.25)	$ 0.23
DILUTED	$ 0.01	$ 0.21	$ (0.25)	$ 0.23
SHARES USED IN COMPUTING INCOME (LOSS) PER SHARE:
BASIC	71,537	61,726	66,088	61,656
DILUTED	72,662	62,143	66,088	62,172
Products and Services [Member]
NET REVENUES:
Total revenue	$ 46,749	$ 35,299	$ 105,972	$ 100,898
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 1,262	$ 690	$ 2,894	$ 4,039

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
NET INCOME (LOSS)	$ 1,040	$ 13,078	$ (16,782)	$ 14,218
OTHER COMPREHENSIVE INCOME (LOSS)
Currency translation adjustments	1,953	(1,557)	(3,542)	3,151
Unrealized gain (loss) on marketable securities	(266)	194	83	877
COMPREHENSIVE INCOME (LOSS)	$ 2,727	$ 11,715	$ (20,241)	$ 18,246

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
OPERATING ACTIVITIES:
Net income (loss)	$ (16,782)	$ 14,218
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation	5,913	3,283
Depreciation and amortization	7,051	5,532
Provision for doubtful accounts	1,141	2,083
Unrealized foreign currency (gain) loss	(41)	272
Interest expense on finance leases	56	23
Deferred income taxes	(764)	(291)
Loss on sale of fixed assets	104	145
Gain on sale of business		(10,149)
Change in the estimated fair value of acquisition-related contingent consideration	390	(843)
Payment of acquisition-related contingent consideration	(496)
Changes in assets and liabilities
Accounts receivable	5,228	5,730
Inventories	(7,425)	(3,255)
Prepaid expenses and other assets	2,420	1,438
Accounts payable	3,269	(1,042)
Deferred revenue	1,664	348
Accrued expenses and other liabilities	468	(6,654)
Net cash provided by operating activities	2,196	10,838
INVESTING ACTIVITIES:
Purchases of investments	(90,137)	(92,173)
Proceeds from maturities and redemptions of investments	102,616	91,451
Purchases of property and equipment	(11,234)	(7,961)
Proceeds from escrow associated with business acquisitions	126
Proceeds from sale of business		12,000
Acquisition of businesses, net of cash acquired	(3,037)	(13,217)
Purchase of patent and product rights	(2,250)
Net cash used in investing activities	(3,916)	(9,900)
FINANCING ACTIVITIES:
Repayments of loans		(724)
Cash payments for lease liabilities	(521)	(253)
Payment of acquisition-related contingent consideration	(3,004)
Issuance of common stock in connection with public offering, net	95,036
Proceeds from exercise of stock options	2,115	169
Repurchase of common stock	(2,076)	(3,711)
Net cash provided by (used in) financing activities	91,550	(4,519)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(2,686)	608
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	87,144	(2,973)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	75,715	88,438
CASH AND CASH EQUIVALENTS, END OF PERIOD	162,859	85,465
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes	3,888	7,470
Non-cash investing and financing activities
Accrued property and equipment purchases	2,093	477
Unrealized gain on marketable securities	$ 83	$ 877

The Company

9 Months Ended

Sep. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

The Company

1.	The Company

Our business consists of two segments: our “OSUR business” primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our molecular products and services business, or “DNAG business” consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets and in the sexually transmitted infection screening market. In addition, our DNAG business provides microbiome laboratory and bioinformatics services.

The OSUR business includes tests for diseases including HIV and Hepatitis C that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our HIV product is also sold in a consumer-friendly format in the over-the-counter (“OTC”) market in the U.S. and as a self-test to individuals in a number of other countries. Our OSUR business includes the operations of UrSure, Inc. (“UrSure”), which was acquired in July 2020. UrSure is developing and commercializing products that measure adherence to HIV medications including pre-exposure prophylaxis or PrEP, the daily medication to prevent HIV. UrSure’s products include laboratory-based tests that can measure levels of the medication in a patient’s urine or blood, as well as several additional point of care products currently in development. We also previously manufactured and sold medical devices used for the removal of benign skin lesions by cryosurgery or freezing. We sold the assets associated with our cryosurgical systems business to a third party in August 2019.

Our DNAG business is operated by our subsidiaries, DNA Genotek Inc. (“DNAG”), Diversigen, Inc. (“Diversigen”), CoreBiome Inc. (“CoreBiome”) and Novosanis NV (“Novosanis”). DNAG’s specimen collection devices provide all-in-one systems for the collection, stabilization, transportation and storage of nucleic acids from human saliva and other sample types for genetic and microbiome applications. CoreBiome and Diversigen provide laboratory and bioinformatics services in the microbiome market. Novosanis’ Colli-Pee collection device is designed for the volumetric collection of first-void urine for use in research, screening and diagnostics for the liquid biopsy and sexually transmitted infection markets. We also sell research use only sample collection products into the microbiome market and we offer our customers a suite of genomics and microbiome services, which range from package customization and study design optimization to extraction, analysis and reporting services. We serve customers worldwide in the research, healthcare, pharmaceutical and agricultural communities.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The accompanying interim unaudited consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNAG, Diversigen, CoreBiome, Novosanis, and UrSure. All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The unaudited financial statements, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019. Results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results of operations expected for the full year.

Summary of Significant Accounting Policies. There have been no changes to the Company's significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 that have had a material impact on the consolidated financial statements and related notes except as discussed herein.

Investments. We consider all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

We record an allowance for credit loss for our available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. As of September 30, 2020, we determined that the decline in the market value of our available-for-sale investment was not due to credit-related factors and as such no allowance for credit-loss was necessary.

The following is a summary of our available-for-sale securities as of September 30, 2020 and December 31, 2019:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
September 30, 2020
Guaranteed investment certificates	$	24,019	$	—	$	—		$	24,019
Corporate bonds		76,814		269		(300	)		76,783
Total available-for-sale securities	$	100,833	$	269	$	(300	)	$	100,802
December 31, 2019
Guaranteed investment certificates	$	24,632	$	—	$	—		$	24,632
Corporate bonds		89,525		271		(385	)		89,411
Total available-for-sale securities	$	114,157	$	271	$	(385	)	$	114,043
At September 30, 2020, maturities of our available-for-sale securities were as follows:
Less than one year	$	72,947	$	228	$	(214	)	$	72,961
Greater than one year	$	27,886	$	41	$	(86	)	$	27,841

Fair Value of Financial Instruments. As of September 30, 2020 and December 31, 2019, the carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 2 instruments as of September 30, 2020 and December 31, 2019.

Included in cash and cash equivalents at September 30, 2020 and December 31, 2019, was $95,254 and $1,624 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds. The fair value of the plan assets as of September 30, 2020 and December 31, 2019 was $3,360 and $3,519, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and noncurrent assets with the same amount included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.

Accounts Receivable. Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.

Property, Plant and Equipment. Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold,

retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property, plant and equipment as of September 30, 2020 and December 31, 2019 was $51,807 and $46,882, respectively.

Intangible Assets. Intangible assets consist of customer relationships, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years. Accumulated amortization of intangible assets as of September 30, 2020 and December 31, 2019 was $25,393 and $23,420, respectively. The increase in intangibles from $14,674 as of December 31, 2019 to $18,111 as of September 30, 2020 is a result of the developed technology acquired in our acquisition of UrSure of $3,400, the acquisition of patent and product rights of $2,250, and foreign currency translation gains of $148 offset by $2,361 in amortization expense.

Goodwill. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

The increase in goodwill from $36,201 as of December 31, 2019 to $39,480 as of September 30, 2020 is a result of the additional goodwill associated with our acquisition of UrSure of $3,739 offset by a purchase price adjustment related to our Diversigen acquisition of $(126), and an adjustment of $(334) associated with foreign currency translation.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than a functional currency are included in our consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains resulting from foreign currency transactions that are included in other income in our consolidated statements of income were $70 and $50 for the three months ended September 30, 2020 and 2019, respectively. Net foreign exchange gains (losses) were $563 and $(875) for the nine months ended September 30, 2020 and 2019.

Accumulated Other Comprehensive Income (Loss). We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations for those subsidiaries are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at September 30, 2020 consists of $15,564 of currency translation adjustments and $31 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investment portfolio. Accumulated other comprehensive loss at December 31, 2019 consists of $12,022 of currency translation adjustments and $114 of net unrealized losses on marketable securities.

Recent Accounting Pronouncements. In June 2016, the FASB issued guidance on the measurement of credit losses, which requires measurement and recognition of expected credit losses for financial assets, including trade receivables and capital lease receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The method to determine a loss requires a credit loss to be recognized when it is probable. We adopted this guidance in the first quarter of 2020 and the impact of the adoption was not material to the Company's consolidated financial statements as credit losses are not expected to be significant based on historical collection trends, the financial condition of payment partners, and external market factors. The Company will continue to actively monitor the impact of the recent coronavirus (COVID-19) pandemic on expected credit losses. In addition, the new guidance requires us to record an allowance for credit loss when a decline in investment market value is due to credit-related factors. As of January 1, 2020, there was no material decline in the market value of available-for-sale investments due to credit-related factors.

In February 2018, the FASB issued guidance allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the U.S. Tax Cuts and Jobs Act. If elected, the reclassification can be applied in either the period of adoption or retrospectively to the period of the enactment of the U.S. Tax Cuts and Jobs Act (i.e., our first quarter of fiscal year 2018). We adopted this guidance in the first quarter of 2020 and the impact of the adoption was not material to the Company's consolidated financial statements.

In August 2018, the FASB issued guidance related to fair value measurement disclosures. This guidance removes the requirement to disclose the amount of and reasons for transfers between Levels 1 and 2 of the fair value hierarchy, the policy for determining that a transfer has occurred, and valuation processes for Level 3 fair value measurements. Additionally, this guidance modifies the disclosures related to the measurement uncertainty for recurring Level 3 fair value measurements (by removing the requirement to disclose sensitivity to future changes) and the timing of liquidation of invested assets (by removing the timing requirement in certain instances). The guidance also requires new disclosures for Level

3 financial assets and liabilities, including the amount and location of unrealized gains and losses recognized in other comprehensive income(loss) and additional information related to significant unobservable inputs used in determining Level 3 fair value measurements. We adopted this guidance in the first quarter of 2020 and the impact of the adoption was not material to the Company's consolidated financial statements.

Business Combinations

9 Months Ended

Sep. 30, 2020

Business Combinations [Abstract]

Business Combinations

3. Business Combinations

UrSure

On July 22, 2020, the Company acquired all of the outstanding stock of UrSure, Inc. (“UrSure”), pursuant to the terms of a merger agreement. The initial aggregate purchase price of this transaction was $3,000, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement.

Pursuant to our acquisition agreements, we may pay up to an additional $28,000 of contingent consideration over the next four years based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, and the development of certain new technology. The Company, with the assistance of an independent valuation specialist, determined the estimated acquisition-date fair value of the acquisition-related contingent consideration of $3,440. The simulation calculated the probability-weighted payments based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. There has been no material change in the fair value of the contingent consideration obligation changed from the acquisition date to September 30, 2020.

During the nine months ended September 30, 2020, we incurred a total of $393 of acquisition related costs, including accounting, legal, and other professional fees, all of which were expensed and reported as a component of general and administrative expense in the consolidated statement of income for the nine months ended September 30, 2020.

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	285
Other current assets		24
Other assets		6
Intangibles		3,400
Goodwill		3,739
Total assets acquired		7,454
Liabilities Assumed
Current liabilities		212
Deferred tax liability		642
Deferred revenue		123
Total liabilities assumed		977
Net Assets Acquired	$	6,477
Estimated fair value of contingent consideration		(3,440	)
Net Cash Paid (net of cash acquired of $111)	$	3,037

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets principally included developed technology, which is subject to amortization on a straight-line basis and is being amortized over a ten year estimated useful life.

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of UrSure. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method.

The amortization of intangible assets is not deductible for income tax purposes.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisition was a result of gaining a complementary service and product offering that will enable us to leverage those services and products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our OSUR segment.

We continue to evaluate the fair value of certain assets acquired and liabilities assumed, related to the acquisition. Additional information that existed as of the acquisition date, but was at that time unknown to us, may become known during the remainder of the measurement period. Changes to amounts recorded as a result of the final determination may result in a corresponding adjustment to these assets and liabilities, including goodwill. The determination of the estimated fair values of all assets acquired is expected to be completed within one year from the date of acquisition.

Revenues from UrSure primarily consist of grant money received to fund the development of certain new technology. Effective as of July 22, 2020, the financial results of UrSure are included in our OSUR segment.

CoreBiome and Novosanis

On January 4, 2019, the Company acquired all of the outstanding stock of CoreBiome, pursuant to the terms of a merger agreement. Also on January 4, 2019, the Company, through a wholly-owned subsidiary, acquired all of the outstanding stock of Novosanis, pursuant to a share purchase agreement. The aggregate purchase price for both of these transactions was $13,320 adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into escrow accounts for a limited period after closing, in order to secure the potential payment of certain indemnification obligations of the selling stockholders under each agreement noted above. See Note 3 set forth in the Company’s audited financial statements included as part of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 for additional information on the CoreBiome and Novosanis acquisitions.

During the nine months ended September 30, 2019, we incurred a total of $597 of acquisition-related costs in connection with these acquisitions, including success-based investment banking fees and accounting, legal and other professional fees, related to both acquisitions, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of operations for the nine months ended September 30, 2019.

Pursuant to our acquisition agreements, we were to pay up to an additional $32,400 of contingent consideration over three years based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, the achievement of a large customer contract, and the development of certain new technology. The Company, with the assistance of an independent valuation specialist, utilized a Monte Carlo simulation to determine the estimated acquisition-date fair value of the acquisition-related contingent consideration of $4,350. The simulation calculated the probability-weighted payments based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration obligation changed from $4,350 as of the acquisition date to $3,424 as of September 30, 2019 as a result of changes in our estimated revenue forecasts. The fair value of the contingent consideration obligation changed from $3,612 as of December 31, 2019 to $500 as of September 30, 2020. This change is a result of a $3,500 payment made in the first quarter of 2020, changes in our estimated revenue forecasts and an amendment to one of the agreements. Pursuant to the amendment, which was entered into in March 2020, the terms of the contingent consideration provisions associated with one of the acquisitions were modified and are expected to be paid during the first quarter of 2021. As of September 30, 2020, we may pay up to an additional $22,500 of contingent consideration through July 2021.

Revenues from CoreBiome primarily consist of fees paid for microbiome laboratory services that utilize optimal analytical algorithms to deliver speed and scalability in the lab with precise analytics. Revenues from Novosanis primarily consist of the sale of its Colli-Pee collection device which was designed for the standard collection of first-void urine used in the liquid biopsy and sexually transmitted infection screening market. Effective as of January 4, 2019, the financial results of CoreBiome and Novosanis are included in our DNAG segment.

Diversigen

On November 8, 2019, the Company acquired all of the outstanding stock of Diversigen pursuant to the terms of a merger agreement. The aggregate purchase price for this transaction was $12,000, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement noted above. See Note 3 set forth in the Company’s audited financial statements included as part of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 for additional information on the Diversigen acquisition.

During the nine months ended September 30, 2019, we did not incur any acquisition related costs associated with this transaction.

Pursuant to the merger agreement, we were to pay up to an additional $1,500 of contingent consideration in 2020 based on the achievement of certain 2019 revenue metrics as defined under the agreements which did not occur.

Revenues from Diversigen primarily consist of fees paid for microbiome laboratory services that provide metagenomics sequencing, bioinformatics and statistical analysis for the study of the microbiome. Effective as of November 8, 2019, the financial results of Diversigen are included in our DNAG segment.

Unaudited Pro Forma Financial Information

The unaudited pro forma results presented below include the results of the CoreBiome, Diversigen, Novosanis and UrSure acquisitions as if they had been consummated as of January 1, 2019. The unaudited pro forma results include the amortization associated with acquired intangible assets and the estimated tax effect of adjustments to income before income taxes but do not include changes in the fair value of our contingent consideration obligations. Material nonrecurring charges, directly attributable to the transactions, including direct acquisition costs, are also excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2019.

	Three Months ended September 30,				Nine Months ended September 30,
	2020		2019		2020			2019

Revenue	$	48,073	$	37,695	$	109,708		$	105,703
Net income (loss)		1,009		12,340		(17,179	)		12,531
Net income (loss) per share, basic and diluted		0.01		0.20		(0.27	)		0.20

Inventories

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Inventories

4. Inventories

	September 30, 2020		December 31, 2019
Raw materials	$	15,913	$	14,168
Work in process		1,277		643
Finished goods		13,298		8,344
	$	30,488	$	23,155

Earnings (Loss) Per Share

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

5. Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.

The computations of basic and diluted earnings (loss) per share are as follows:

	Three Months				Nine Months
	Ended September 30,				Ended September 30,
	2020		2019		2020			2019

Net income (loss)	$	1,040	$	13,078	$	(16,782	)	$	14,218
Weighted-average shares of common stock outstanding:
Basic		71,537		61,726		66,088			61,656
Dilutive effect of stock options, restricted stock, and performance stock units		1,125		417		—			516
Diluted		72,662		62,143		66,088			62,172
Earnings (loss) per share:
Basic	$	0.01	$	0.21	$	(0.25	)	$	0.23
Diluted	$	0.01	$	0.21	$	(0.25	)	$	0.23

For the nine months ended September 30, 2020, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 917 shares were excluded from the computation of diluted loss per share as their inclusion would have been anti-dilutive. For the three months ended September 30, 2020 and 2019, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 136 and 909 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2019, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 709 shares were excluded from the computation of diluted earnings per share.

Revenues

9 Months Ended

Sep. 30, 2020

Revenue From Contract With Customer [Abstract]

Revenues

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2020		2019			2020		2019
Infectious disease testing	$	13,224	$	13,588		$	36,625	$	39,284
Risk assessment testing		2,316		3,312			6,848		9,246
Cryosurgical systems		—		961			—		7,054
Genomics		8,519		13,647			23,381		35,438
Microbiome		1,828		1,878			4,259		5,325
COVID-19		18,441		—			27,307		—
Laboratory services		2,418		1,617			7,472		3,947
Other product revenue		3		296			80		604
Net product and services revenues		46,749		35,299			105,972		100,898
Royalty income		450		758			1,623		2,956
Other non product revenues		812		(68	)		1,271		1,083
Other revenues		1,262		690			2,894		4,039
Net revenues	$	48,011	$	35,989		$	108,866	$	104,937

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
United States	$	38,594	$	26,245	$	82,125	$	74,712
Europe		2,789		2,767		8,663		8,188
Other regions		6,628		6,977		18,078		22,037
	$	48,011	$	35,989	$	108,866	$	104,937

Customer and Vendor Concentrations. We had no significant customer concentrations (greater than 10%) in our accounts receivable at September 30, 2020. One of our customers accounted for 19% of our accounts receivable as of December 31, 2019. One customer accounted for 11% of net consolidated revenues for the three months ended September 30, 2020. Another customer accounted for approximately 17% and 11% of our net consolidated revenues for the three and nine months ended September 30, 2019.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our

products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its product. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of September 30, 2020 and December 31, 2019 includes customer prepayments of $3,525 and $1,904, respectively. Deferred revenue as of September 30, 2020 and December 31, 2019 also includes $1,786 and $1,809, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that average price.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Accrued Expenses and Other Current Liabilities

9 Months Ended

Sep. 30, 2020

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

7.	Accrued Expenses and other current liabilities

	September 30, 2020		December 31, 2019
Payroll and related benefits	$	8,553	$	6,088
Professional fees		1,293		2,769
Other		5,301		5,431
	$	15,147	$	14,288

Leases

9 Months Ended

Sep. 30, 2020

Lessee Disclosure [Abstract]

Leases

We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of September 30, 2020, we are the lessee in all agreements. Our leases have remaining lease terms of 1 to 7 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components.

The components of lease expense are as follows:

	Three Months Ended				Nine Months Ended
	2020		2019		2020		2019
Operating Lease Cost	$	330	$	232	$	964	$	695
Finance Lease Cost
Amortization of right-of use assets		150		112		476		264
Interest on lease liabilities		17		10		56		23
Total Finance Lease Cost	$	167	$	122	$	532	$	287

Supplemental cash flow information related to leases is as follows:

	Nine Months Ended
	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	965	$	690
Operating cash flows from financing leases		56		23
Financing cash flows from financing leases		521		253
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations		498		240
Right-of-use assets obtained in exchange for finance lease obligations		46		1,249

Supplemental balance sheet information related to leases is as follows:

	September 30, 2020		December 31, 2019
Operating Leases
Right-of-use assets	$	4,682	$	4,996

Current lease liabilities		1,092		1,032
Non-current lease liabilities		3,848		4,206
Total operating lease liabilities	$	4,940	$	5,238


Finance Leases
Right-of-use assets	$	1,462	$	1,951

Current lease liabilities		536		613
Non-current lease liabilities		1,025		1,372
Total finance lease liabilities	$	1,561	$	1,985

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	4.66
Weighted-average remaining lease term—finance leases	2.87

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.25	%
Weighted-average discount rate—finance leases	4.34	%

As of September 30, 2020, minimum lease payments by period are expected to be as follows:


	Finance			Operating
2020 (excluding the nine months ended September 30, 2020)	$	166		$	330
2021		566			1,311
2022		566			1,294
2023		336			872
2024		25			893
Thereafter		4			841
Total Minimum Lease Payments		1,663			5,541
Less: imputed interest		(102	)		(601	)
Present Value of Lease Liabilities	$	1,561		$	4,940

Stockholders' Equity

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Stockholders' Equity

9.Stockholders’ Equity

Reconciliation of the changes in stockholders' equity for the three and nine months ended September 30, 2020 and 2019
	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2019		61,731		$	—	$	401,814		$	(12,136	)	$	(82,533	)	$	307,145
Common stock issued upon exercise of options		6			—		30			—			—			30
Vesting of restricted stock and performance stock units		486			—		—			—			—			—
Purchase and retirement of common shares		(197	)		—		(1,408	)		—			—			(1,408	)
Stock-based compensation		—			—		1,376			—			—			1,376
Net loss		—			—		—			—			(7,328	)		(7,328	)
Currency translation adjustments		—			—		—			(9,221	)		—			(9,221	)
Unrealized loss on marketable securities		—			—		—			(442	)		—			(442	)
Balance at March 31, 2020		62,026		$	—	$	401,812		$	(21,799	)	$	(89,861	)	$	290,152
Common stock issued upon exercise of options		71			—		530			—			—			530
Vesting of restricted stock and performance stock units		161			—		—			—			—			—
Purchase and retirement of common shares		(50	)		—		(656	)		—			—			(656	)
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200		9,200			—		95,036			—			—			95,036
Stock-based compensation		—			—		2,672			—			—			2,672
Net loss		—			—		—			—			(10,494	)		(10,494	)
Currency translation adjustments		—			—		—			3,726			—			3,726
Unrealized gain on marketable securities		—			—		—			791			—			791
Balance at June 30, 2020		71,408		$	—	$	499,394		$	(17,282	)	$	(100,355	)	$	381,757
Common stock issued upon exercise of options		202			—		1,555			—			—			1,555
Vesting of restricted stock and performance stock units		2			—		—			—			—			—
Purchase and retirement of common shares		(1	)		—		(12	)		—			—			(12	)
Stock-based compensation		—			—		1,865			—			—			1,865
Net income		—			—		—			—			1,040			1,040
Currency translation adjustments		—			—		—			1,953			—			1,953
Unrealized loss on marketable securities		—			—		—			(266	)		—			(266	)
Balance at September 30, 2020		71,611		$	—	$	502,802		$	(15,595	)	$	(99,315	)	$	387,892


	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2018		61,276		$	—	$	401,273		$	(18,706	)	$	(99,189	)	$	283,378
Common stock issued upon exercise of options		4			—		22			—			—			22
Vesting of restricted stock and performance stock units		664			—		—			—			—			—
Purchase and retirement of common shares		(277	)		—		(3,595	)		—			—			(3,595	)
Stock-based compensation		—			—		1,231			—			—			1,231
Net loss		—			—		—			—			(3,258	)		(3,258	)
Currency translation adjustments		—			—		—			2,232			—			2,232
Unrealized gain on marketable securities		—			—		—			497			—			497
Balance at March 31, 2019		61,667		$	—	$	398,931		$	(15,977	)	$	(102,447	)	$	280,507
Common stock issued upon exercise of options		18			—		147			—			—			147
Vesting of restricted stock and performance stock units		51			—		—			—			—			—
Purchase and retirement of common shares		(11	)		—		(109	)		—			—			(109	)
Stock-based compensation		—			—		616			—			—			616
Net income		—			—		—			—			4,398			4,398
Currency translation adjustments		—			—		—			2,476			—			2,476
Unrealized gain on marketable securities		—			—		—			186			—			186
Balance at June 30, 2019		61,725		$	—	$	399,585		$	(13,315	)	$	(98,049	)	$	288,221
Common stock issued upon exercise of options		—			—		—			—			—			—
Vesting of restricted stock and performance stock units		2			—		—			—			—			—
Purchase and retirement of common shares		(1	)		—		(7	)		—			—			(7	)
Stock-based compensation		—			—		1,436			—			—			1,436
Net income		—			—		—			—			13,078			13,078
Currency translation adjustments		—			—		—			(1,557	)		—			(1,557	)
Unrealized gain on marketable securities		—			—		—			194			—			194
Balance at September 30, 2019		61,726		$	—	$	401,014		$	(14,678	)	$	(84,971	)	$	301,365

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than shares purchased on the open market.

Total compensation cost related to stock options for the nine months ended September 30, 2020 and 2019 was $683 and $894 respectively.

Compensation cost of $3,329 and $2,385 related to restricted shares was recognized during the nine months ended September 30, 2020 and 2019, respectively.

We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain employed for three years from the grant date. Performance during the one-year period is based

on a one-year earnings per share or income before income taxes target. If the one-year target is achieved, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested.

Compensation cost of $1,901 and $4 related to PSUs was recognized during the nine months ended September 30, 2020 and 2019, respectively.

In connection with the vesting of restricted shares and PSU’s during the nine months ended September 30, 2020 and 2019, we purchased and immediately retired 248 and 289 shares with aggregate values of $2,076 and $3,711, respectively, in satisfaction of minimum tax withholding obligations.

Public Offering

On June 1, 2020, we entered into an underwriting agreement with J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Evercore Group LLC, as representatives of several underwriters, relating to the issuance and sale of 8,000 shares of our common stock. The price to the public in the offering was $11.00 per share. Under the terms of the underwriting agreement, we also granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,200 shares of common stock. On June 3, 2020, we announced the full exercise by the underwriters of their option to purchase these additional shares.

The offering was made pursuant to an effective registration statement on Form S-3 (File No. 333-228877) we had previously filed with the SEC, and a prospectus supplement thereunder. The net proceeds from the offering were approximately $95,000 after deducting underwriting discounts and offering expenses paid by the Company.

Stock Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired during the nine months ended September 30, 2020 and 2019.

Income Taxes

9 Months Ended

Sep. 30, 2020

Income Tax Disclosure [Abstract]

Income Taxes

10.	Income Taxes

During the three and nine months ended September 30, 2020, we recorded income tax expense of $3,659 and $5,680, respectively, which primarily consists of foreign tax expense. During the three and nine months ended September 30, 2019, we recorded income tax expense of $1,169 and $2,551, which also primarily consists of a foreign tax expense.

Tax expense reflects taxes due to the taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of September 30, 2020 and December 31, 2019 relate to the tax effects of the basis difference between the intangible assets acquired in our acquisitions for financial reporting and for tax purposes.

In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate at both September 30,2020 and December 31, 2019 since the facts and circumstances necessitating the allowance have not changed.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

11.	Commitments and Contingencies

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

Business Segment Information

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Business Segment Information

12.	Business Segment Information

Our business consists of two segments: our “OSUR” business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our OSUR segment includes the financial results of UrSure. Our “DNAG” business consists of the development, manufacture, marketing and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets; and in the sexually transmitted infection screening market. In addition, our DNAG business provides microbiome laboratory services that accelerate research and discovery for customers in the pharmaceutical, agricultural, and academic research markets. Financial results of Diversigen, CoreBiome and Novosanis are included in our DNAG segment. Our cryosurgical systems business was included in our OSUR segment and the impact of the sale of that business in August 2019 is reflected in the results presented below.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

The following table summarizes operating segment information for the three and nine months ended September 30, 2020 and 2019, and asset information as of September 30, 2020 and December 31, 2019:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2020			2019		2020			2019
Net revenues:
OSUR	$	16,314		$	17,730	$	44,533		$	56,335
DNAG		31,697			18,259		64,333			48,602
Total	$	48,011		$	35,989	$	108,866		$	104,937
Operating income (loss):
OSUR	$	(9,951	)	$	8,080	$	(31,116	)	$	4,595
DNAG		14,336			4,972		18,054			9,931
Total	$	4,385		$	13,052	$	(13,062	)	$	14,526
Depreciation and amortization:
OSUR	$	934		$	889	$	2,681		$	2,555
DNAG		1,517			1,033		4,370			2,977
Total	$	2,451		$	1,922	$	7,051		$	5,532
Capital expenditures:
OSUR	$	2,186		$	1,796	$	5,634		$	5,341
DNAG		3,011			652		5,600			2,620
Total	$	5,197		$	2,448	$	11,234		$	7,961

	September 30, 2020		December 31, 2019
Total assets:
OSUR	$	260,167	$	163,943
DNAG		176,243		185,352
Total	$	436,410	$	349,295

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Investments

The following is a summary of our available-for-sale securities as of September 30, 2020 and December 31, 2019:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
September 30, 2020
Guaranteed investment certificates	$	24,019	$	—	$	—		$	24,019
Corporate bonds		76,814		269		(300	)		76,783
Total available-for-sale securities	$	100,833	$	269	$	(300	)	$	100,802
December 31, 2019
Guaranteed investment certificates	$	24,632	$	—	$	—		$	24,632
Corporate bonds		89,525		271		(385	)		89,411
Total available-for-sale securities	$	114,157	$	271	$	(385	)	$	114,043
At September 30, 2020, maturities of our available-for-sale securities were as follows:
Less than one year	$	72,947	$	228	$	(214	)	$	72,961
Greater than one year	$	27,886	$	41	$	(86	)	$	27,841

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 2 instruments as of September 30, 2020 and December 31, 2019.

Accounts Receivable

Property, Plant and Equipment

Intangible Assets

Goodwill

Foreign Currency Translation

Accumulated Other Comprehensive Income (Loss)

Recent Accounting Pronouncements

Revenues by Product

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2020		2019			2020		2019
Infectious disease testing	$	13,224	$	13,588		$	36,625	$	39,284
Risk assessment testing		2,316		3,312			6,848		9,246
Cryosurgical systems		—		961			—		7,054
Genomics		8,519		13,647			23,381		35,438
Microbiome		1,828		1,878			4,259		5,325
COVID-19		18,441		—			27,307		—
Laboratory services		2,418		1,617			7,472		3,947
Other product revenue		3		296			80		604
Net product and services revenues		46,749		35,299			105,972		100,898
Royalty income		450		758			1,623		2,956
Other non product revenues		812		(68	)		1,271		1,083
Other revenues		1,262		690			2,894		4,039
Net revenues	$	48,011	$	35,989		$	108,866	$	104,937

Revenues by Geographic Area

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
United States	$	38,594	$	26,245	$	82,125	$	74,712
Europe		2,789		2,767		8,663		8,188
Other regions		6,628		6,977		18,078		22,037
	$	48,011	$	35,989	$	108,866	$	104,937

Customer and Vendor Concentrations

Deferred Revenue

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Summary of Available-for-sale Securities

The following is a summary of our available-for-sale securities as of September 30, 2020 and December 31, 2019:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
September 30, 2020
Guaranteed investment certificates	$	24,019	$	—	$	—		$	24,019
Corporate bonds		76,814		269		(300	)		76,783
Total available-for-sale securities	$	100,833	$	269	$	(300	)	$	100,802
December 31, 2019
Guaranteed investment certificates	$	24,632	$	—	$	—		$	24,632
Corporate bonds		89,525		271		(385	)		89,411
Total available-for-sale securities	$	114,157	$	271	$	(385	)	$	114,043
At September 30, 2020, maturities of our available-for-sale securities were as follows:
Less than one year	$	72,947	$	228	$	(214	)	$	72,961
Greater than one year	$	27,886	$	41	$	(86	)	$	27,841

Business Combinations (Tables)

9 Months Ended

Sep. 30, 2020

Business Combinations [Abstract]

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	285
Other current assets		24
Other assets		6
Intangibles		3,400
Goodwill		3,739
Total assets acquired		7,454
Liabilities Assumed
Current liabilities		212
Deferred tax liability		642
Deferred revenue		123
Total liabilities assumed		977
Net Assets Acquired	$	6,477
Estimated fair value of contingent consideration		(3,440	)
Net Cash Paid (net of cash acquired of $111)	$	3,037

Summary of Unaudited Pro Forma Financial Information

	Three Months ended September 30,				Nine Months ended September 30,
	2020		2019		2020			2019

Revenue	$	48,073	$	37,695	$	109,708		$	105,703
Net income (loss)		1,009		12,340		(17,179	)		12,531
Net income (loss) per share, basic and diluted		0.01		0.20		(0.27	)		0.20

Inventories (Tables)

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Schedule of Inventories

	September 30, 2020		December 31, 2019
Raw materials	$	15,913	$	14,168
Work in process		1,277		643
Finished goods		13,298		8,344
	$	30,488	$	23,155

Earnings (Loss) Per Share (Tables)

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Computations of Basic and Diluted Earnings (Loss) Per Share

The computations of basic and diluted earnings (loss) per share are as follows:

	Three Months				Nine Months
	Ended September 30,				Ended September 30,
	2020		2019		2020			2019

Net income (loss)	$	1,040	$	13,078	$	(16,782	)	$	14,218
Weighted-average shares of common stock outstanding:
Basic		71,537		61,726		66,088			61,656
Dilutive effect of stock options, restricted stock, and performance stock units		1,125		417		—			516
Diluted		72,662		62,143		66,088			62,172
Earnings (loss) per share:
Basic	$	0.01	$	0.21	$	(0.25	)	$	0.23
Diluted	$	0.01	$	0.21	$	(0.25	)	$	0.23

Revenues (Tables)

9 Months Ended

Sep. 30, 2020

Revenue From Contract With Customer [Abstract]

Disaggregation of Revenue by Product and Geographic Area

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2020		2019			2020		2019
Infectious disease testing	$	13,224	$	13,588		$	36,625	$	39,284
Risk assessment testing		2,316		3,312			6,848		9,246
Cryosurgical systems		—		961			—		7,054
Genomics		8,519		13,647			23,381		35,438
Microbiome		1,828		1,878			4,259		5,325
COVID-19		18,441		—			27,307		—
Laboratory services		2,418		1,617			7,472		3,947
Other product revenue		3		296			80		604
Net product and services revenues		46,749		35,299			105,972		100,898
Royalty income		450		758			1,623		2,956
Other non product revenues		812		(68	)		1,271		1,083
Other revenues		1,262		690			2,894		4,039
Net revenues	$	48,011	$	35,989		$	108,866	$	104,937

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
United States	$	38,594	$	26,245	$	82,125	$	74,712
Europe		2,789		2,767		8,663		8,188
Other regions		6,628		6,977		18,078		22,037
	$	48,011	$	35,989	$	108,866	$	104,937

Accrued Expenses and Other Current Liabilities (Tables)

9 Months Ended

Sep. 30, 2020

Payables And Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

	September 30, 2020		December 31, 2019
Payroll and related benefits	$	8,553	$	6,088
Professional fees		1,293		2,769
Other		5,301		5,431
	$	15,147	$	14,288

Leases (Tables)

9 Months Ended

Sep. 30, 2020

Lessee Disclosure [Abstract]

Summary of Components of Lease Expense

The components of lease expense are as follows:

	Three Months Ended				Nine Months Ended
	2020		2019		2020		2019
Operating Lease Cost	$	330	$	232	$	964	$	695
Finance Lease Cost
Amortization of right-of use assets		150		112		476		264
Interest on lease liabilities		17		10		56		23
Total Finance Lease Cost	$	167	$	122	$	532	$	287

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:

	Nine Months Ended
	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	965	$	690
Operating cash flows from financing leases		56		23
Financing cash flows from financing leases		521		253
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations		498		240
Right-of-use assets obtained in exchange for finance lease obligations		46		1,249

Summary of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases is as follows:

	September 30, 2020		December 31, 2019
Operating Leases
Right-of-use assets	$	4,682	$	4,996

Current lease liabilities		1,092		1,032
Non-current lease liabilities		3,848		4,206
Total operating lease liabilities	$	4,940	$	5,238


Finance Leases
Right-of-use assets	$	1,462	$	1,951

Current lease liabilities		536		613
Non-current lease liabilities		1,025		1,372
Total finance lease liabilities	$	1,561	$	1,985

Summary of Lease Term and Discount Rate

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	4.66
Weighted-average remaining lease term—finance leases	2.87

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.25	%
Weighted-average discount rate—finance leases	4.34	%

Schedule of Minimum Lease Payments by Period Expected

As of September 30, 2020, minimum lease payments by period are expected to be as follows:


	Finance			Operating
2020 (excluding the nine months ended September 30, 2020)	$	166		$	330
2021		566			1,311
2022		566			1,294
2023		336			872
2024		25			893
Thereafter		4			841
Total Minimum Lease Payments		1,663			5,541
Less: imputed interest		(102	)		(601	)
Present Value of Lease Liabilities	$	1,561		$	4,940

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Summary of Reconciliation of Changes in Stockholders' Equity

Reconciliation of the changes in stockholders' equity for the three and nine months ended September 30, 2020 and 2019
	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2019		61,731		$	—	$	401,814		$	(12,136	)	$	(82,533	)	$	307,145
Common stock issued upon exercise of options		6			—		30			—			—			30
Vesting of restricted stock and performance stock units		486			—		—			—			—			—
Purchase and retirement of common shares		(197	)		—		(1,408	)		—			—			(1,408	)
Stock-based compensation		—			—		1,376			—			—			1,376
Net loss		—			—		—			—			(7,328	)		(7,328	)
Currency translation adjustments		—			—		—			(9,221	)		—			(9,221	)
Unrealized loss on marketable securities		—			—		—			(442	)		—			(442	)
Balance at March 31, 2020		62,026		$	—	$	401,812		$	(21,799	)	$	(89,861	)	$	290,152
Common stock issued upon exercise of options		71			—		530			—			—			530
Vesting of restricted stock and performance stock units		161			—		—			—			—			—
Purchase and retirement of common shares		(50	)		—		(656	)		—			—			(656	)
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200		9,200			—		95,036			—			—			95,036
Stock-based compensation		—			—		2,672			—			—			2,672
Net loss		—			—		—			—			(10,494	)		(10,494	)
Currency translation adjustments		—			—		—			3,726			—			3,726
Unrealized gain on marketable securities		—			—		—			791			—			791
Balance at June 30, 2020		71,408		$	—	$	499,394		$	(17,282	)	$	(100,355	)	$	381,757
Common stock issued upon exercise of options		202			—		1,555			—			—			1,555
Vesting of restricted stock and performance stock units		2			—		—			—			—			—
Purchase and retirement of common shares		(1	)		—		(12	)		—			—			(12	)
Stock-based compensation		—			—		1,865			—			—			1,865
Net income		—			—		—			—			1,040			1,040
Currency translation adjustments		—			—		—			1,953			—			1,953
Unrealized loss on marketable securities		—			—		—			(266	)		—			(266	)
Balance at September 30, 2020		71,611		$	—	$	502,802		$	(15,595	)	$	(99,315	)	$	387,892


	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2018		61,276		$	—	$	401,273		$	(18,706	)	$	(99,189	)	$	283,378
Common stock issued upon exercise of options		4			—		22			—			—			22
Vesting of restricted stock and performance stock units		664			—		—			—			—			—
Purchase and retirement of common shares		(277	)		—		(3,595	)		—			—			(3,595	)
Stock-based compensation		—			—		1,231			—			—			1,231
Net loss		—			—		—			—			(3,258	)		(3,258	)
Currency translation adjustments		—			—		—			2,232			—			2,232
Unrealized gain on marketable securities		—			—		—			497			—			497
Balance at March 31, 2019		61,667		$	—	$	398,931		$	(15,977	)	$	(102,447	)	$	280,507
Common stock issued upon exercise of options		18			—		147			—			—			147
Vesting of restricted stock and performance stock units		51			—		—			—			—			—
Purchase and retirement of common shares		(11	)		—		(109	)		—			—			(109	)
Stock-based compensation		—			—		616			—			—			616
Net income		—			—		—			—			4,398			4,398
Currency translation adjustments		—			—		—			2,476			—			2,476
Unrealized gain on marketable securities		—			—		—			186			—			186
Balance at June 30, 2019		61,725		$	—	$	399,585		$	(13,315	)	$	(98,049	)	$	288,221
Common stock issued upon exercise of options		—			—		—			—			—			—
Vesting of restricted stock and performance stock units		2			—		—			—			—			—
Purchase and retirement of common shares		(1	)		—		(7	)		—			—			(7	)
Stock-based compensation		—			—		1,436			—			—			1,436
Net income		—			—		—			—			13,078			13,078
Currency translation adjustments		—			—		—			(1,557	)		—			(1,557	)
Unrealized gain on marketable securities		—			—		—			194			—			194
Balance at September 30, 2019		61,726		$	—	$	401,014		$	(14,678	)	$	(84,971	)	$	301,365

Business Segment Information (Tables)

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the three and nine months ended September 30, 2020 and 2019, and asset information as of September 30, 2020 and December 31, 2019:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2020			2019		2020			2019
Net revenues:
OSUR	$	16,314		$	17,730	$	44,533		$	56,335
DNAG		31,697			18,259		64,333			48,602
Total	$	48,011		$	35,989	$	108,866		$	104,937
Operating income (loss):
OSUR	$	(9,951	)	$	8,080	$	(31,116	)	$	4,595
DNAG		14,336			4,972		18,054			9,931
Total	$	4,385		$	13,052	$	(13,062	)	$	14,526
Depreciation and amortization:
OSUR	$	934		$	889	$	2,681		$	2,555
DNAG		1,517			1,033		4,370			2,977
Total	$	2,451		$	1,922	$	7,051		$	5,532
Capital expenditures:
OSUR	$	2,186		$	1,796	$	5,634		$	5,341
DNAG		3,011			652		5,600			2,620
Total	$	5,197		$	2,448	$	11,234		$	7,961

	September 30, 2020		December 31, 2019
Total assets:
OSUR	$	260,167	$	163,943
DNAG		176,243		185,352
Total	$	436,410	$	349,295

The Company - Additional Information (Detail)	9 Months Ended
The Company - Additional Information (Detail)	Sep. 30, 2020 Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of Segments of company	2

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 100,833	$ 114,157
Gross Unrealized Gains	269	271
Gross Unrealized Losses	(300)	(385)
Fair Value	100,802	114,043
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	24,019	24,632
Gross Unrealized Gains	0	0
Fair Value	24,019	24,632
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	76,814	89,525
Gross Unrealized Gains	269	271
Gross Unrealized Losses	(300)	(385)
Fair Value	76,783	$ 89,411
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	72,947
Gross Unrealized Gains	228
Gross Unrealized Losses	(214)
Fair Value	72,961
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	27,886
Gross Unrealized Gains	41
Gross Unrealized Losses	(86)
Fair Value	$ 27,841

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jul. 22, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents		$ 162,859		$ 162,859		$ 75,715
Fair value of plan assets		3,360		3,360		3,519
Accumulated depreciation of property and equipment		51,807		51,807		46,882
Accumulated amortization of intangible assets		25,393		25,393		23,420
Intangible Assets, Net		18,111		18,111		14,674
Intangible Assets, Accumulated Amortization				2,361
Intangible Assets, Foreign currency translation gains				148
Amount of goodwill at period end		39,480		39,480		36,201
Adjustment in goodwill associated with foreign currency translation				(334)
Net foreign exchange gains (losses)		70	$ 50	563	$ (875)
Accumulated foreign currency adjustments included in other comprehensive loss amounted		15,564		15,564		12,022
Unrealized loss on marketable securities		31		31		114
UrSure Inc [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Acquired intangibles, amount	$ 3,400
Amount of goodwill at period end	$ 3,739	3,739		3,739
Diversigen, Inc. [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Goodwill, acquired during period				(126)
Patent and Product Rights [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Patent and product rights acquisition				2,250
Developed Technology [Member] \| UrSure Inc [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	10 years
Acquired intangibles, amount		3,400		$ 3,400
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)				5 years
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)				15 years
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				10 years
Money Market Fund [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents		$ 95,254		$ 95,254		$ 1,624

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands				3 Months Ended	9 Months Ended
	Jul. 22, 2020	Nov. 08, 2019	Jan. 04, 2019	Mar. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Business Acquisition [Line Items]
Business acquisition contingent consideration, non-current					$ 3,176		$ 112
Maximum [Member]
Business Acquisition [Line Items]
Intangible Assets, Amortization Period (Years)					15 years
Minimum [Member]
Business Acquisition [Line Items]
Intangible Assets, Amortization Period (Years)					5 years
UrSure Inc [Member]
Business Acquisition [Line Items]
Purchase price	$ 3,000
Business acquisition contingent consideration, non-current	$ 28,000
Business combination contingent consideration expected payment period	4 years
Estimated fair value of contingent consideration	$ 3,440
Acquisition-related costs					$ 393
UrSure Inc [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Intangible Assets, Amortization Period (Years)	10 years
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Purchase price			$ 13,320
Business acquisition contingent consideration, non-current			$ 32,400
Business combination contingent consideration expected payment period			3 years		1 year
Estimated fair value of contingent consideration			$ 4,350				$ 3,612
Acquisition-related costs						$ 597
Business acquisition contingent consideration					$ 500	3,424
Payment of acquisition-related contingent consideration				$ 3,500
Corebiome Inc. and Novosanis NV [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Business acquisition contingent consideration, non-current					22,500
Diversigen, Inc. [Member]
Business Acquisition [Line Items]
Purchase price		$ 12,000
Business acquisition contingent consideration, non-current					$ 1,500
Acquisition-related costs						$ 0
Business combination contingent consideration expected payment year					2020

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Jul. 22, 2020	Dec. 31, 2019
Assets Acquired
Goodwill	$ 39,480		$ 36,201
UrSure Inc [Member]
Assets Acquired
Accounts receivable		$ 285
Other current assets		24
Other assets		6
Intangibles		3,400
Goodwill	$ 3,739	3,739
Total assets acquired		7,454
Liabilities Assumed
Current liabilities		212
Deferred tax liability		642
Deferred revenue		123
Total liabilities assumed		977
Net Assets Acquired		6,477
Estimated fair value of contingent consideration		(3,440)
Net Cash Paid (net of cash acquired of $111)		$ 3,037

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) - USD ($) $ in Thousands		9 Months Ended
	Jul. 22, 2020	Sep. 30, 2020	Sep. 30, 2019
Business Acquisition [Line Items]
Net of cash acquired		$ 3,037	$ 13,217
UrSure Inc [Member]
Business Acquisition [Line Items]
Net of cash acquired	$ 111

Business Combinations - Summary of Unaudited Pro Forma Financial Information (Detail) - CoreBiome Inc. Diversign Novosanis NV and UrSure [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Business Acquisition [Line Items]
Revenue	$ 48,073	$ 37,695	$ 109,708	$ 105,703
Net income (loss)	$ 1,009	$ 12,340	$ (17,179)	$ 12,531
Net income (loss) per share, basic and diluted	$ 0.01	$ 0.20	$ (0.27)	$ 0.20

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Net [Abstract]
Raw materials	$ 15,913	$ 14,168
Work in process	1,277	643
Finished goods	13,298	8,344
Inventories	$ 30,488	$ 23,155

Earnings (Loss) Per Share - Computations of Basic and Diluted Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
NET INCOME (LOSS)	$ 1,040	$ (10,494)	$ (7,328)	$ 13,078	$ 4,398	$ (3,258)	$ (16,782)	$ 14,218
SHARES USED IN COMPUTING INCOME (LOSS) PER SHARE:
BASIC	71,537			61,726			66,088	61,656
Dilutive effect of stock options, restricted stock, and performance stock units	1,125			417				516
Diluted	72,662			62,143			66,088	62,172
BASIC	$ 0.01			$ 0.21			$ (0.25)	$ 0.23
DILUTED	$ 0.01			$ 0.21			$ (0.25)	$ 0.23

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Earnings (Loss) Per Share - Additional Information (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Common Stock Options Unvested Restricted Stock and Unvested Performance Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Number of anti-dilutive securities excluded from EPS computation	136	909	917	709

Revenues - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation Of Revenue [Line Items]
Net revenues	$ 48,011	$ 35,989	$ 108,866	$ 104,937
Product and Services Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	46,749	35,299	105,972	100,898
Product and Services Revenues [Member] \| Infectious Disease Testing [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	13,224	13,588	36,625	39,284
Product and Services Revenues [Member] \| Risk Assessment Testing [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,316	3,312	6,848	9,246
Product and Services Revenues [Member] \| Cryosurgical Systems [Member]
Disaggregation Of Revenue [Line Items]
Net revenues		961		7,054
Product and Services Revenues [Member] \| Genomics [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	8,519	13,647	23,381	35,438
Product and Services Revenues [Member] \| Microbiome [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	1,828	1,878	4,259	5,325
Product and Services Revenues [Member] \| COVID-19 [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	18,441		27,307
Product and Services Revenues [Member] \| Laboratory Services [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,418	1,617	7,472	3,947
Product and Services Revenues [Member] \| Other Product Revenue [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	3	296	80	604
Other [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	1,262	690	2,894	4,039
Other [Member] \| Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	450	758	1,623	2,956
Other [Member] \| Other Non Product Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 812	$ (68)	$ 1,271	$ 1,083

Revenues - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation Of Revenue [Line Items]
Net revenues	$ 48,011	$ 35,989	$ 108,866	$ 104,937
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	38,594	26,245	82,125	74,712
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,789	2,767	8,663	8,188
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 6,628	$ 6,977	$ 18,078	$ 22,037

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Revenues - Additional Information (Detail) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
Revenues - Additional Information (Detail) $ in Thousands	Sep. 30, 2020 USD ($) Supplier	Sep. 30, 2019	Sep. 30, 2020 USD ($) Supplier	Sep. 30, 2019	Dec. 31, 2019 USD ($)
Revenue from contract with customer [Line Items]
Deferred revenue	$ 5,311		$ 5,311		$ 3,713
Long-term Contract [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	1,786		1,786		1,809
Up Front Payment Arrangement [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	$ 3,525		$ 3,525		$ 1,904
DNA Genotek [Member]
Revenue from contract with customer [Line Items]
Number of third-party suppliers to manufacture DNAG's products \| Supplier	2		2
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk					19.00%
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Maximum [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk			10.00%
Customer [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk	11.00%	17.00%		11.00%

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accrued Liabilities Current [Abstract]
Payroll and related benefits	$ 8,553	$ 6,088
Professional fees	1,293	2,769
Other	5,301	5,431
Accrued expenses and other current liabilities, Total	$ 15,147	$ 14,288

Leases - Additional Information (Detail)	9 Months Ended
Leases - Additional Information (Detail)	Sep. 30, 2020
Lessee Lease Description [Line Items]
Lessee operating and financing lease existence of option to terminate	true
Lessee operating and financing leases, period of options to terminate	1 year
Lessee, operating and finance lease, existence of option to extend	true
Minimum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	7 years

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Lease Cost [Abstract]
Operating Lease Cost	$ 330	$ 232	$ 964	$ 695
Finance Lease Cost
Amortization of right-of use assets	150	112	476	264
Interest on lease liabilities	17	10	56	23
Total Finance Lease Cost	$ 167	$ 122	$ 532	$ 287

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 965	$ 690
Operating cash flows from financing leases	56	23
Financing cash flows from financing leases	521	253
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	498	240
Right-of-use assets obtained in exchange for finance lease obligations	$ 46	$ 1,249

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Operating Leases
Right-of-use assets	$ 4,682	$ 4,996
Current lease liabilities	1,092	1,032
Non-current lease liabilities	3,848	4,206
Total operating lease liabilities	4,940	5,238
Finance Leases
Right-of-use assets	1,462	1,951
Current lease liabilities	536	613
Non-current lease liabilities	1,025	1,372
Total finance lease liabilities	$ 1,561	$ 1,985

Leases - Summary of Lease Term and Discount Rate (Detail)	Sep. 30, 2020
Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	4 years 7 months 28 days
Weighted-average remaining lease term—finance leases	2 years 10 months 13 days
Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.25%
Weighted-average discount rate—finance leases	4.34%

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Finance Lease Liabilities, Payments, Due [Abstract]
2020 (excluding the nine months ended September 30, 2020)	$ 166
2021	566
2022	566
2023	336
2024	25
Thereafter	4
Total Minimum Finance Lease Payments	1,663
Less: imputed interest	(102)
Present Value of Finance Lease Liabilities	1,561	$ 1,985
Operating Lease Liabilities, Payments Due [Abstract]
2020 (excluding the nine months ended September 30, 2020)	330
2021	1,311
2022	1,294
2023	872
2024	893
Thereafter	841
Total Minimum Operating Lease Payments	5,541
Less: imputed interest	(601)
Present Value of Operating Lease Liabilities	$ 4,940	$ 5,238

Stockholders' Equity - Summary of Reconciliation of Changes in Stockholders' Equity (Parenthetical) (Detail) $ in Thousands	3 Months Ended
	Jun. 30, 2020 USD ($)
Equity [Abstract]
Issuance of common stock in connection with public offering, net of commissions and expenses	$ 6,200

Stockholders' Equity - Summary of Reconciliation of Changes in Stockholders' Equity (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Beginning Balance	$ 381,757	$ 290,152	$ 307,145	$ 288,221	$ 280,507	$ 283,378	$ 307,145	$ 283,378
Common stock issued upon exercise of options	1,555	530	30		147	22
Purchase and retirement of common shares	(12)	(656)	(1,408)	(7)	(109)	(3,595)
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200		95,036
Stock-based compensation	1,865	2,672	1,376	1,436	616	1,231
Net income (loss)	1,040	(10,494)	(7,328)	13,078	4,398	(3,258)	(16,782)	14,218
Currency translation adjustments	1,953	3,726	(9,221)	(1,557)	2,476	2,232	(3,542)	3,151
Unrealized gain (loss) on marketable securities	(266)	791	(442)	194	186	497	83	877
Ending Balance	$ 387,892	$ 381,757	$ 290,152	$ 301,365	$ 288,221	$ 280,507	$ 387,892	$ 301,365
Common Stock [Member]
Beginning Balance, Shares	71,408	62,026	61,731	61,725	61,667	61,276	61,731	61,276
Common stock issued upon exercise of options, Shares	202	71	6		18	4
Vesting of restricted stock and performance stock units, Shares	2	161	486	2	51	664
Purchase and retirement of common shares, Shares	(1)	(50)	(197)	(1)	(11)	(277)
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200, Shares		9,200
Ending Balance, Shares	71,611	71,408	62,026	61,726	61,725	61,667	71,611	61,726
Additional Paid-in Capital [Member]
Beginning Balance	$ 499,394	$ 401,812	$ 401,814	$ 399,585	$ 398,931	$ 401,273	$ 401,814	$ 401,273
Common stock issued upon exercise of options	1,555	530	30		147	22
Purchase and retirement of common shares	(12)	(656)	(1,408)	(7)	(109)	(3,595)
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200		95,036
Stock-based compensation	1,865	2,672	1,376	1,436	616	1,231
Ending Balance	502,802	499,394	401,812	401,014	399,585	398,931	502,802	401,014
Accumulated Other Comprehensive Loss [Member]
Beginning Balance	(17,282)	(21,799)	(12,136)	(13,315)	(15,977)	(18,706)	(12,136)	(18,706)
Currency translation adjustments	1,953	3,726	(9,221)	(1,557)	2,476	2,232
Unrealized gain (loss) on marketable securities	(266)	791	(442)	194	186	497
Ending Balance	(15,595)	(17,282)	(21,799)	(14,678)	(13,315)	(15,977)	(15,595)	(14,678)
Accumulated Deficit [Member]
Beginning Balance	(100,355)	(89,861)	(82,533)	(98,049)	(102,447)	(99,189)	(82,533)	(99,189)
Net income (loss)	1,040	(10,494)	(7,328)	13,078	4,398	(3,258)
Ending Balance	$ (99,315)	$ (100,355)	$ (89,861)	$ (84,971)	$ (98,049)	$ (102,447)	$ (99,315)	$ (84,971)

Stockholders' Equity - Additional Information (Detail) - USD ($)		9 Months Ended
	Jun. 01, 2020	Sep. 30, 2020	Sep. 30, 2019	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		$ 5,913,000	$ 3,283,000
Amount share repurchase program of common shares				$ 25,000,000
Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance and sale of common stock	8,000,000
Public offering price per share	$ 11.00
Net offering proceeds after deducting underwriting discount and commission and offering expenses	$ 95,000,000
Over-Allotment Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Underwriters option exercisable period	30 days
Underwriters option to purchase additional shares	$ 1,200,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		683,000	894,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		$ 3,329,000	2,385,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		$ 1,901,000	$ 4,000
Restricted Stock and PSU's [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting of restricted shares, withholding and exercise obligations		248,000	289,000
Restricted shares of common stock, aggregate values		$ 2,076,000	$ 3,711,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired		0	0

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 3,659	$ 1,169	$ 5,680	$ 2,551

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Business Segment Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2020 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Segment Reporting Information [Line Items]
Net revenues	$ 48,011	$ 35,989	$ 108,866	$ 104,937
Operating income (loss)	4,385	13,052	(13,062)	14,526
Depreciation and amortization	2,451	1,922	7,051	5,532
Capital expenditures	5,197	2,448	11,234	7,961
Total assets	436,410		436,410		$ 349,295
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues	16,314	17,730	44,533	56,335
Operating income (loss)	(9,951)	8,080	(31,116)	4,595
Depreciation and amortization	934	889	2,681	2,555
Capital expenditures	2,186	1,796	5,634	5,341
Total assets	260,167		260,167		163,943
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues	31,697	18,259	64,333	48,602
Operating income (loss)	14,336	4,972	18,054	9,931
Depreciation and amortization	1,517	1,033	4,370	2,977
Capital expenditures	3,011	$ 652	5,600	$ 2,620
Total assets	$ 176,243		$ 176,243		$ 185,352

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599